Table 2.
Patient baseline characteristics of the validation cohort
| Characteristics | HC (n = 15) (%) | Patient (n = 60) |
||
|---|---|---|---|---|
| CHB (n = 15) (%) | LC (n = 15) (%) | HCC (n = 30) (%) | ||
| Age (year) | ||||
| Mean ± SD | 43.9 ± 11.9 | 43.3 ± 8.5 | 49.2 ± 7.1 | 56.5 ± 10.6 |
| Sex | ||||
| Male | 13 (86.7) | 13 (86.7) | 13 (86.7) | 26 (86.7) |
| Female | 2 (13.3) | 2 (13.3) | 2 (13.3) | 4 (13.3) |
| HBsAg | ||||
| Yes | \ | 15 (100) | 29 (100) | 30 (100) |
| No | \ | 0 | 0 | 0 |
| Child-Pugh | ||||
| A | \ | \ | 5 (33.3) | 20 (66.7) |
| B | \ | \ | 5 (33.3) | 9 (30) |
| C | \ | \ | 5 (33.3) | 1 (3.3) |
| TNM Stage | ||||
| I | \ | \ | \ | 10 (33.3) |
| II | \ | \ | \ | 10 (33.3) |
| III | \ | \ | \ | 10 (33.3) |
HBsAg, Hepatitis B surface antigen.